These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Effect of intravenous vitamin C on cytokine activation and oxidative stress in end-stage renal disease patients receiving intravenous iron sucrose. Conner TA, McQuade C, Olp J, Pai AB. Biometals; 2012 Oct; 25(5):961-9. PubMed ID: 22706571 [Abstract] [Full Text] [Related]
27. Comparative rates of adverse events with different formulations of intravenous iron. Okam MM, Mandell E, Hevelone N, Wentz R, Ross A, Abel GA. Am J Hematol; 2012 Nov; 87(11):E123-4. PubMed ID: 22965928 [Abstract] [Full Text] [Related]
29. Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease. Erichsen K, Ulvik RJ, Grimstad T, Berstad A, Berge RK, Hausken T. Aliment Pharmacol Ther; 2005 Nov 01; 22(9):831-8. PubMed ID: 16225492 [Abstract] [Full Text] [Related]
30. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products. McCarthy JT, Regnier CE, Loebertmann CL, Bergstralh EJ. Am J Nephrol; 2000 Nov 01; 20(6):455-62. PubMed ID: 11146312 [Abstract] [Full Text] [Related]
31. Relationship between insulin resistance and erythropoietin responsiveness in hemodialysis patients. Abe M, Okada K, Soma M, Matsumoto K. Clin Nephrol; 2011 Jan 01; 75(1):49-58. PubMed ID: 21176750 [Abstract] [Full Text] [Related]
35. Differences between original intravenous iron sucrose and iron sucrose similar preparations. Toblli JE, Cao G, Oliveri L, Angerosa M. Arzneimittelforschung; 2009 Jan 01; 59(4):176-90. PubMed ID: 19517894 [Abstract] [Full Text] [Related]
37. The comparative safety of various intravenous iron preparations in chronic kidney disease patients. Anirban G, Kohli HS, Jha V, Gupta KL, Sakhuja V. Ren Fail; 2008 Jan 01; 30(6):629-38. PubMed ID: 18661414 [Abstract] [Full Text] [Related]
38. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Van Wyck DB, Cavallo G, Spinowitz BS, Adhikarla R, Gagnon S, Charytan C, Levin N. Am J Kidney Dis; 2000 Jul 01; 36(1):88-97. PubMed ID: 10873877 [Abstract] [Full Text] [Related]
39. Accumulation of circulating advanced oxidation protein products is an independent risk factor for ischaemic heart disease in maintenance haemodialysis patients. Zhou Q, Wu S, Jiang J, Tian J, Chen J, Yu X, Chen P, Mei C, Xiong F, Shi W, Zhou W, Liu X, Sun S, Xie DI, Liu J, Xu X, Liang M, Hou F. Nephrology (Carlton); 2012 Sep 01; 17(7):642-9. PubMed ID: 22738256 [Abstract] [Full Text] [Related]